Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial
Chris Cobourn
Advertisement
Articles by Chris Cobourn
Advertisement
Latest Updated Articles
- Lessons learned on bona fide service fees and fair market value-is there a 'right answer'?
Published: April 30th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
WeightWatchers to Offer Novo Nordisk’s Oral Wegovy, if Approved Next Year
2
Pharma Pulse: FDA Advances New Approval Pathway, as Obesity Care and Metabolic Treatments Gain Momentum
3
Pharma Pulse: FDA Appoints Richard Pazdur as CDER Director Amid 340B Tensions and Novartis Expansion
4
Bridging the Vendor Compliance Confidence Gap in Life Sciences
5
